Diuretic-resistant congestive heart failure treated successfully with peritoneal ultrafiltration

Próchnicka, Agnieszka; Krzesiński, Paweł; Hałas, Katarzyna; Dziuk, Mirosław; Niemczyk, Stanisław; Wańkowicz, Z

doi:10.5603/kp.2013.0067

Cited by 4 publications

(1 citation statement)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…When the technique is implemented in a situation of acute heart decompensation, low volumes must be used (750 to 1000 mL), and the dialysis must be changed often (approximately every 1 -2 hours), with dialysis solutions based on icodextrin (a glucose polymer with a high ultrafiltration potential) or hypertonic glucose, in order to prevent complications, such as the pericatheter leakage of peritoneal fluid [10,11].…”

Section: Peritoneal Dialysismentioning

confidence: 99%

Role of different kinds of dialysis in the treatment of refractory heart failure

Rosado¹,

Manzanedo²,

Felipe³

et al. 2014

JBiSE

View full text Add to dashboard Cite

Cardiorenal syndrome is a severe and potentially lethal disease in which heart and kidney failures coexist. The classic treatment with loop diuretics is ineffective due to the resistance of the kidney to those drugs, which requires the use of other therapies, such as extracorporeal ultrafiltration and peritoneal dialysis. This last technique is useful both in the acute treatment of acute heart decompensation and the chronic management of heart failure, because it improves heart function by reducing the volume overload, which in turn contributes to improving the kidney function with a limited number of side effects, which makes it the technique of choice for the treatment of diuretic-resistant heart failure. In this review, we present a description of the different kinds of cardiorenal syndrome, as well as the different treatments that are used, with special attention to the different modalities of peritoneal dialysis.

show abstract

Section: Peritoneal Dialysismentioning

confidence: 99%

Role of different kinds of dialysis in the treatment of refractory heart failure

Rosado¹,

Manzanedo²,

Felipe³

et al. 2014

JBiSE

View full text Add to dashboard Cite

show abstract

Extending the role of peritoneal dialysis: can we win hearts and minds?

Davies¹,

Lally²,

Satchithananda³

et al. 2014

Nephrology Dialysis Transplantation

View full text Add to dashboard Cite

show abstract

Effectiveness and Safety of Peritoneal Dialysis Treatment in Patients with Refractory Congestive Heart Failure due to Chronic Cardiorenal Syndrome

Shao

Xia

Zhao

et al. 2018

BioMed Research International

View full text Add to dashboard Cite

Aims To evaluate the effectiveness and safety of peritoneal dialysis (PD) in treating refractory congestive heart failure (RCHF) with cardiorenal syndrome (CRS). Methods A total of 36 patients with RCHF were divided into type 2 CRS group (group A) and non-type 2 CRS group (group B) according to the patients' clinical presentations and the ratio of serum urea to creatinine and urinary analyses in this prospective study. All patients were followed up till death or discontinuation of PD. Data were collected for analysis, including patient survival time on PD, technique failure, changes of heart function, and complications associated with PD treatment and hospitalization. Results There were 27 deaths and 9 patients quitting PD program after a follow-up for 73 months with an average PD time of 22.8 ± 18.2 months. A significant longer PD time was found in group B as compared with that in group A (29.0 ± 19.4 versus 13.1 ± 10.6 months, p = 0.003). Kaplan–Meier curves showed a higher survival probability in group B than that in group A (p < 0.001). Multivariate regression demonstrated that type 2 CRS was an independent risk factor for short survival time on PD. The benefit of PD on the improvement of survival and LVEF was limited to group B patients, but absent from group A patients. The impairment of exercise tolerance indicated by NYHA classification was markedly improved by PD for both groups. The technique survival was high, and the hospital readmission was evidently decreased for both group A and group B patients. Conclusions Our data suggest that PD is a safe and feasible palliative treatment for RCHF with type 2 CRS, though the long-term survival could not be expected for patients with the type 2 CRS. Registration ID Number is ChiCTR1800015910.

show abstract

Diuretic-resistant congestive heart failure treated successfully with peritoneal ultrafiltration

Cited by 4 publications

References 8 publications

Role of different kinds of dialysis in the treatment of refractory heart failure

Role of different kinds of dialysis in the treatment of refractory heart failure

Extending the role of peritoneal dialysis: can we win hearts and minds?

Effectiveness and Safety of Peritoneal Dialysis Treatment in Patients with Refractory Congestive Heart Failure due to Chronic Cardiorenal Syndrome

Contact Info

Product

Resources

About